Peter Radovich Sells 2,631 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 2,631 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $271,782.30. Following the completion of the sale, the chief operating officer directly owned 20,655 shares of the company’s stock, valued at $2,133,661.50. The trade was a 11.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Peter Radovich also recently made the following trade(s):

• On Monday, January 26th, Peter Radovich sold 3,143 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $96.19, for a total transaction of $302,325.17.
• On Thursday, January 22nd, Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $222,312.06.

Mirum Pharmaceuticals Trading Down 1.4%

NASDAQ MIRM opened at $103.96 on Thursday. The firm’s fifty day moving average is $82.21 and its two-hundred day moving average is $73.54. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $105.74. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The firm has a market cap of $5.34 billion, a PE ratio of -120.88 and a beta of 0.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. The firm had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The business’s revenue was up 47.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.30) earnings per share. Analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. CWM LLC lifted its stake in shares of Mirum Pharmaceuticals by 30.8% during the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after buying an additional 161 shares during the period. Legal & General Group Plc raised its holdings in Mirum Pharmaceuticals by 0.4% in the 2nd quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock valued at $2,189,000 after acquiring an additional 176 shares during the last quarter. MCF Advisors LLC raised its holdings in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after acquiring an additional 185 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in shares of Mirum Pharmaceuticals by 2.2% during the 2nd quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock worth $504,000 after purchasing an additional 215 shares during the period. Finally, Jones Financial Companies Lllp boosted its holdings in shares of Mirum Pharmaceuticals by 34.0% during the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after purchasing an additional 243 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MIRM. Stifel Nicolaus boosted their price objective on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Evercore ISI reaffirmed an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Finally, JMP Securities set a $95.00 price objective on Mirum Pharmaceuticals in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $107.25.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.